

Datasheet for ABIN1589828
anti-FLT4 antibody



[Go to Product page](#)

1 Publication

Overview

Quantity:	100 µg
Target:	FLT4
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This FLT4 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunoprecipitation (IP), Immunohistochemistry (Acetone-fixed) (IHC (af))

Product Details

Purpose:	VEGFR-3/FLT-4 antibody
Immunogen:	Recombinant human sFLT-4 (D1-7) (ABIN1589554 and ABIN1589553)
Isotype:	IgG
Specificity:	Recombinant human sFLT-4 (D1-7)
Characteristics:	Chromosomal location: 5q35.3 Produced from sera of rabbits immunised with highly pure recombinant human soluble VEGFR-3/FLT-4 (D1-D7).
Purification:	Anti-human VEGFR-3/FLT-4 was purified by antigen-affinity chromatography with immobilised soluble VEGFR-3/FLT-4.

Target Details

Target:	FLT4
Alternative Name:	VEGFR-3/FLT-4 (FLT4 Products)
Background:	Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4, Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1-D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.
Gene ID:	2324
NCBI Accession:	NM_002020 , NP_002011
UniProt:	P35916
Pathways:	RTK Signaling , Signaling Events mediated by VEGFR1 and VEGFR2 , VEGF Signaling

Application Details

Application Notes:	Western Blot: Use 1-5 µg/mL
Restrictions:	For Research Use only

Handling

Format:	Lyophilized
Reconstitution:	Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.
Buffer:	PBS
Handling Advice:	Centrifuge vial prior to opening.
Storage:	4 °C, -20 °C
Storage Comment:	The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the

Handling

antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Expiry Date: 24 months

Publications

Product cited in: Liu, Li, Zhang, Rao, Liang, Liu: "The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia." in: **Placenta**, Vol. 36, Issue 3, pp. 279-86, (2015) ([PubMed](#)).